Business
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price
Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss Brief Summary: Wegovy® HD is
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nExpands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss\n\n\nBrief Summary:\n\n\n\nWegovy® HD is now available on GoodRx at a self-pay price of $399 per month\n\n\n\nPricing scales to $798 for two-month supply and $1,197 for three-month supply\n\n\n\nAvailable at pharmacies nationwide through GoodRx\n\n\n\nConsumers can determine eligibility and obtain a prescription through GoodRx for Weight Loss\n\n\n\n \n\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.\n\n\n“Pharmaceutical innovation is moving quickly to meet the evolving needs of patients, and access has to keep pace,” said Wendy Barnes, President & CEO at GoodRx. “Wegovy HD is a strong example of how manufacturers are expanding options to support patients at different stages of treatment. GoodRx is proud to help translate that innovation into real-world access, connecting patients to the FDA-approved therapies and dosing they need with clear, predictable pricing.”\n\n\nAs demand for GLP-1 treatments continues to grow, many consumers are navigating access outside of traditional insurance coverage. GoodRx simplifies that experience by surfacing upfront pricing and connecting it directly to nationwide pharmacy access, helping consumers understand their options before they reach the pharmacy counter.\n\n\n“We’re continuing to expand the Wegovy® portfolio with a simple goal: give patients the right option at the right time in their treatment,” said Ed Cinca senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Wegovy® HD adds another FDA-approved option to meet patients’ clinical needs. Working with GoodRx helps make these medicines e...